US equities |
MU $877.55 ▲+2.46% NVDA $210.96 ▼-0.59% SPCX $147.49 ▲+1.89% AAPL $347.73 ▼-0.14% TSLA $372.22 ▼-0.63% SNDK $1,238.03 ▼-1.82% META $642.62 ▼-0.96% AMD $516.79 ▲+1.74%
FinancialContent

Enlivex Ltd. - Ordinary Shares (NQ:ENLV)

0.1734 -0.0258 (-12.95%)
Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Enlivex Ltd. - Ordinary Shares

< Previous 1 2 3 4 Next >
News headline image
Enlivex Announces 1-for-16 Reverse Share Split to be Effective October 27, 2026
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex Announces Cost Reduction Plan to Focus Resources on Phase 2b Trial of Allocetra™ in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex Announces Termination of Previously-Announced Financing Payable in RAIN Tokens
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex Announces $400,000,000 Private Placement
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading Volume
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis
From Enlivex Ltd.
Via GlobeNewswire
News headline image
ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory Board
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex Posts $1.23B Profit (Net Income) For Fiscal 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Off The Hook Yachts and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
News headline image
Enlivex Treasury Portfolio Update: New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency Exchange
From Enlivex Therapeutics Ltd
Via GlobeNewswire
News headline image
RedChip Fintech & DATS Conference Replays Now Available Featuring Public Companies Shaping the Future of Digital Finance
Via ACCESS Newswire
< Previous 1 2 3 4 Next >